Literature DB >> 9642078

Structural basis for the high affinity of amino-aromatic SH2 phosphopeptide ligands.

J Rahuel1, C García-Echeverría, P Furet, A Strauss, G Caravatti, H Fretz, J Schoepfer, B Gay.   

Abstract

An anthranyl moiety placed at the N terminus of a phosphotyrosine peptide potentiates the inhibitory effect of this small peptide on the binding of the Grb2 SH2 domain to the EGF receptor. Using molecular modeling procedures based on the Lck SH2 domain structure, this observation was rationalized in terms of a suitably favorable pi-pi stacking interaction between the anthranyl moiety and the arginine alphaA2 (ArgalphaA2) residue side-chain of Grb2 SH2. The crystal structure of the Grb2 SH2 domain in complex with the inhibitor 2-Abz-EpYINQ-NH2 (IC50 26 nM) has been solved in two different crystal forms at 2.1 and 1.8 A resolution. This structure confirms the modeling based on the Lck SH2 domain. The ArgalphaA2 residue is conserved in most SH2 domains. Thus, as expected, the anthranyl group also confers high affinity to small peptide ligands of other SH2 domains such as Lck-, PLC-gamma-amino-terminal and p85 amino-terminal SH2 domains as demonstrated by structure affinity relationships (SAR) data. These potent peptides with an amino-terminal surrogate group and the structure of Grb2 SH2 domain in complex with one such peptide represent good starting points for the design and optimization of new inhibitors of many SH2 domains. Copyright 1998 Academic Press Limited.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9642078     DOI: 10.1006/jmbi.1998.1790

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  9 in total

1.  Protein-ligand interactions: probing the energetics of a putative cation-π interaction.

Authors:  James M Myslinski; John H Clements; Stephen F Martin
Journal:  Bioorg Med Chem Lett       Date:  2014-05-09       Impact factor: 2.823

2.  Backbone nuclear relaxation characteristics and calorimetric investigation of the human Grb7-SH2/erbB2 peptide complex.

Authors:  Monika Ivancic; Anne M Spuches; Ethan C Guth; Margaret A Daugherty; Dean E Wilcox; Barbara A Lyons
Journal:  Protein Sci       Date:  2005-06       Impact factor: 6.725

3.  Binding of flexible and constrained ligands to the Grb2 SH2 domain: structural effects of ligand preorganization.

Authors:  John H Clements; John E DeLorbe; Aaron P Benfield; Stephen F Martin
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-09-18

4.  The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia.

Authors:  Yonglan Liu; Hyunbum Jang; Mingzhen Zhang; Chung-Jung Tsai; Ryan Maloney; Ruth Nussinov
Journal:  Biophys J       Date:  2022-05-31       Impact factor: 3.699

5.  Solution structure of the human Grb7-SH2 domain/erbB2 peptide complex and structural basis for Grb7 binding to ErbB2.

Authors:  Monika Ivancic; Roger J Daly; Barbara A Lyons
Journal:  J Biomol NMR       Date:  2003-11       Impact factor: 2.835

6.  Structural and energetic aspects of Grb2-SH2 domain-swapping.

Authors:  Aaron P Benfield; Benjamin B Whiddon; John H Clements; Stephen F Martin
Journal:  Arch Biochem Biophys       Date:  2007-04-02       Impact factor: 4.013

7.  Synthesis and structural characterization of a monocarboxylic inhibitor for GRB2 SH2 domain.

Authors:  Tao Xiao; Luxin Sun; Min Zhang; Zilu Li; Eric B Haura; Ernst Schonbrunn; Haitao Ji
Journal:  Bioorg Med Chem Lett       Date:  2021-09-07       Impact factor: 2.823

8.  High resolution crystal structure of the Grb2 SH2 domain with a phosphopeptide derived from CD28.

Authors:  Kunitake Higo; Teikichi Ikura; Masayuki Oda; Hisayuki Morii; Jun Takahashi; Ryo Abe; Nobutoshi Ito
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

9.  Development of Grb2 SH2 Domain Signaling Antagonists: A Potential New Class of Antiproliferative Agents.

Authors:  Terrence R Burke
Journal:  Int J Pept Res Ther       Date:  2006-03-14       Impact factor: 1.931

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.